PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results

• Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval • Phase 3 SHIELD II t rial a dvanced ; preparations underway to i nitiate by y ear-end 2020 • Conference Call S cheduled for t oday at 8:30 a . m .